| abstract |
The present invention relates to novel, stable recombinant gamma interferons exhibiting in greater or less degree the antiviral and antiproliferative activity in humans and pH 2 labile properties characteristic of native human gamma interferon. The amino acid sequence of such an interferon comprises, from the N-terminus: <IMAGE> wherein X is a methionine residue or hydrogen and Y is a glutamine residue or, where X is hydrogen, Y is either a glutamine or a pyroglutamate residue. |